Guobang Pharma Ltd (605507): Kapitalflussrechnung
| Preis (11.09.2026) | 52W Hoch | 52W Tief |
| 15,69 Renminbi Yuan | 20,824 Renminbi Yuan | 14,34 Renminbi Yuan |
| Analysten Konsens | Buy | Outperform | Hold | Underperform | Sell |
| 24 Renminbi Yuan | - | - | - | - | - |
| #Shares | Short [%] | Short Ratio |
| 782.352.900 | - | - |
Kennzahl in 1000 CNY | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|---|---|---|---|---|
Umsatz | 6.011.397,499 | 5.890.839,205 | 5.349.447,852 | 5.720.924,721 | 4.505.350,58 | 4.206.317,952 | 3.802.036,232 | 3.279.017,182 | 2.905.475,181 |
Cashflow aus operativer Geschäftstätigkeit | 559.278,16 | 706.410,855 | 516.760,952 | 1.017.033,878 | -176.183,25 | 767.704,803 | 440.863,592 | 541.682,929 | 148.033 |
▸ Operative Cashflow Marge | 9,3% | 11,99% | 9,66% | 17,78% | -3,91% | 18,25% | 11,6% | 16,52% | 5,09% |
Investitionsausgaben (CapEx) | 277.711,058 | 419.124,791 | 748.441,052 | 803.115,418 | 448.044,14 | 520.158,78 | 605.180,993 | 163.244,507 | 169.476,69 |
Cashflow aus Investitionstätigkeit | - | -513.845,962 | -353.265,043 | -411.764,292 | -1.689.835,734 | -365.231,856 | -307.341,977 | -146.190,862 | -77.199,411 |
Cashflow aus Finanzierungstätigkeit | - | -386.493,994 | -54.136,061 | 366.954,44 | 1.570.519,275 | -273.859,322 | -47.017,463 | -214.244,56 | -97.751,826 |
Freier Cashflow | 281.567,102 | 287.286,064 | -231.680,1 | 213.918,46 | -624.227,39 | 247.546,023 | -164.317,401 | 378.438,422 | -21.443,69 |
▸ Freie Cashflow Marge | 4,68% | 4,88% | -4,33% | 3,74% | -13,86% | 5,89% | -4,32% | 11,54% | -0,74% |
Ausgeschüttete Dividenden | -359.627,313 | -194.101,417 | -361.636,062 | -111.764,7 | -279.411,75 | -152.000 | -34.060,782 | -31.349,281 | -46.405,455 |
Neuausgabe und Rückkäufe von Stammaktien | - | -101.006,281 | - | - | 22.176,933 | 5.047,169 | - | - | - |
Kennzahlen dieser Seite im Lexikon
Weitere Informationen findest du im Takani-Lexikon.